Sign up for ICER's Weekly View Newsletter

 

Weekly View


November 13, 2026

From the desk of Priya Ranade

Good morning, everyone.

Patients and patient groups play a critical role in helping ICER better understand the impacts of a disease, the diversity of the lived experience, and what truly matters to patients when it comes to new treatments. Only when that input is made central to the assessment of value can we meaningfully judge the evidence on how well treatments improve the quality and length of patients’ lives.

 

Given that the patient experience is core to the ICER review process, we recently revamped the ICER Patient Portal, which we initially launched in 2021. Over the past five years, we sought feedback from patient advocates, the ICER Patient Council, and many others on ways to continue adapting the Patient Portal to better meet the needs of the patient community. We’ve spent the better part of 2026 incorporating that feedback into this new layout, which includes the following pages:

 

Patient Portal Landing Page, which links to:

 

The goal of this redesign was to make it easier to understand ICER’s mission, process, and impact. If you have any questions, please reach out to Cat Koola Fischer, ICER’s Senior Director of Patient Engagement, at ckoola@icer.org.

 

And of course, please feel free to share any constructive feedback on this updated Patient Portal.

Let's see what else happened this week...

 

ICER in the News

 

Is Trump’s most-favoured-nation drug policy keeping medicine from Canada? Evidence is mixed

The Globe and the Mail

The Globe and the Mail looked into how MFN policy may be affecting the launch of new medications in Canada. ICER’s IgA Nephropathy assessment was cited as part of the analysis. The article also quoted ICER’s conclusion that:


"'Manufacturers should set prices that will foster affordability and good access for all patients by aligning prices with the patient-centered therapeutic value of their treatments,’ the non-profit’s [ICER] review says.’”

 
 
Pharmaceutical News

MUST READS


Trump’s drug pricing deals force tough choices on launches

Endpoints News

The “most favored nation” (MFN) pricing policy seeks to tie US drug prices to those charged in other wealthy countries. When releasing a new medication, drugmakers have to choose between: accepting lower prices, which drags down profit in the far more lucrative US market; putting pressure on other global markets to pay more; or launching their new drug in only the US.

 

In third-quarter earnings calls, executives at US and European pharmaceutical companies for the first time detailed some of the tangible ways they might protect their US prices, including delaying European launches, seeking favorable reference pricing from countries like Japan and even looking at private-pay options over government-negotiated rates. The comments signal to foreign governments that the threat of delayed drug launches is real, while also offering a glimpse into internal deliberations over where and when to introduce new medicines.

US FDA shelves commissioner's voucher program for speedy drug reviews, sources say

Reuters

The US Food and Drug Administration has shelved the fast-track drug review initiative launched during the Trump administration by former Commissioner Marty Makary, according to six sources familiar with the matter and internal documents.


Launched in June 2025, the Commissioner's National Priority Voucher program aimed to slash drug review timelines to just one to two months ​for therapies addressing national priorities, such as urgent unmet health needs. However, critics pointed to possible preferential treatment for companies meeting demands of President Donald Trump, like offering ‌drugs at lower prices.

CMS Retains ‘Value Of 12’ For One-Time Therapies In Medicare Price Negotiation Despite Pushback

Pink Sheet

CMS will count any one-time therapy as 12 thirty-day periods, roughly a year, when comparing prices in Medicare negotiation. Industry argued the calculation understates durable therapies, saying a $300,000 cell therapy would appear 2.5 times pricier than a $10,000 monthly infusion instead of far cheaper. 


CMS is weighing an outlier policy, but the final rule applies the value of 12 starting with initial price applicability year 2029.

Wyden Open To Codifying Trump MFN Deals In Exchange For Expanding IRA Drug Negotiation

Inside Health Policy

Senate Finance Committee ranking Democrat Ron Wyden (OR), the committee’s likely next chair, told reporters Monday (Nov. 9) that negotiation is “on the table” for a potential agreement to codify the Trump administration’s “most favored nation” agreements with drug companies in exchange for expanding the number of drugs that can be selected for Medicare price negotiations. But he said Democrats still need transparency from the Trump administration on what exactly the deals include.

BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries

STAT

The Biotechnology Innovation Organization is joining the legal fight against the Trump administration’s pilot program aimed at aligning drug prices in Medicare with prices charged in peer countries.  


BIO and two California-based biotech trade groups filed a complaint in the U.S. District Court for the Northern District of California asserting that the Global Benchmark for Efficient Drug Pricing demonstration, known as GLOBE, oversteps Medicare’s statutory authority. The complaint seeks to halt the model.

OTHER HEADLINES

 
 

Key Upcoming Dates

 
  • 11/30: Hypertension — Final Evidence Report
  • 12/10: Friedrich's Ataxia — Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email